Tony Hagen is senior managing editor for The Center for Biosimilars®.
Reports From Biocon, Celltrion on Finances, COVID-19 Treatments
Biocon tests the waters with itolizumab in pandemic-ravaged India, and Celltrion announces early success with an agent for the South African variant.
Amgen, Merck, Teva Provide First-Quarter Biosimilars Info
There's no end in sight for Enbrel (etanercept) sales erosion, but Amgen's biosimilars are holding their own, the company reported.
Cyltezo Is a Contender for First Interchangeable to Humira, Boehringer Ingelheim Says
The results of Voltaire-X could persuade the FDA to authorize automatic substitution of the adalimumab biosimilar Cyltezo for its reference product (Humira), investigators believe.
Toothful or Toothless? Biden's Biosimilar Bills Under the Microscope
How much muscle did Congress invest in a pair of bills recently signed by President Biden? The answer may lie in your willingness to believe.
Kaiser Permanente Study Demonstrates Equivalence for Mvasi
Investigators tapped health system data to conduct an observational, real-world comparison of bevacizumab (Mvasi) vs the reference product (Avastin).
Samsung Bioepis Racks Up More Awards for Its Biosimilar Packaging
Medicinal packaging shouldn't remind patients that they have a condition, according to Samsung Bioepis.
Medicines for Europe Panel Tackles Biosimilar Uptake
The European Union is a diverse market with pockets of biosimilar resistance but also cost-saving triumphs, panelists said at the Biosimilar Medicines Virtual Summit 2021.
New Brunswick, Canada, Switches Patients to Biosimilars
Following the lead of British Columbia and Alberta, New Brunswick, a heavily forested province located between Nova Scotia and Quebec, hopes to save on biologics.
Roche Sees Rejuvenation Amid Sales Declines From Biosimilars, COVID-19
Roche has begun another year of biosimilar sales erosion, although the company has said this year will not be as bad as 2020.
Panel: Should Biologics Manufacturers Have to Disclose More About Their Patents?
More disclosures, earlier in the biosimilar application process, might lead to more competition in biologics, but panelists said this could go too far.
Study: Investigators Report Superior Adherence, Savings for Biosimilars
Weaker persistency and strong adherence were observed among patients taking biosimilar forms of epoetin alfa and infliximab, among others.
British Columbia Switches From Humira to 5 Biosimilar Versions
Anticipating roughly $26 million in annual savings, British Columbia's public payer PharmaCare is switching patients away from originator Humira.
Study: Step Therapy Contributes to Biosimilar Utilization
Study authors measured savings, conversions to biosimilars, and payer policies for 3 originator brands
Prestige BioPharma Sets Up Second Russian Distribution Deal
Russia's land area is vast relative to its population, but Prestige Biopharma eyes an ample market for its bevacizumab biosimilar candidate (HD204).
Biologics Legislation Is Headed to Biden's Desk for Signature
US senators hope to spread the word about biosimilars and limit product exclusivity protections to those products that truly deserve them.
New York Medicaid Ramps Up Biosimilar Use
New York Medicaid achieved 78% to 94% biosimilar utilization for 4 originator brands during a focused effort in 2019.
NORC: Pricing Transparency Could Aid Biosimilar Uptake
This is the second of a 2-part series on a study from the independent research center NORC at University of Chicago concerning biosimilar acceptance and uptake.
NORC: Doctors Must Overcome Patient Hesitation on Biosimilars
This is the first of a 2-part series on a study from the independent research center NORC at University of Chicago concerning biosimilar acceptance and uptake.
News Roundup: Bio-Thera, Henlius Advance Biologics Development
Shanghai Henlius Biotech says the market for a checkpoint inhibitor in China is wide open, and Biogen and Bio-Thera stake out a global map for their tocilizumab biosimilar.
COA Panel Says Confidence Rests on Real-World Data
Next-stage biosimlar acceptance will stand on the strength and availability of real-world data as more of these biologics are launched, a Community Oncology Alliance (COA) conference panel said.
COA's Okon Takes Aim at Biosimilar Misconceptions
Calls for price regulation and lopsided incentives are threats to biosimilar progress, Community Oncology Alliance (COA) Executive Director Ted Okon argues.
PlantForm Will Challenge Merck's Dominance for Pembrolizumab
PlantForm will use tobacco plants to develop antibodies for its checkpoint inhibitor pembrolizumab biosimilar.
Shanghai Henlius Biotech Maps Out Its Biosimilars Future
Shanghai Henlius Biotech began as a 2-person enterprise in 2010 and now has multiple oncology products in development and 3 biosimilars on the market. An executive discusses its business trajectory.
Stada Launches Bevacizumab Biosimilar
Seeking to develop a biosimilar portfolio, Stada Arzneimittel has launched Oyavas in Germany and the Netherlands.
CHMP Gives Remsima SC a Positive Recommendation
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a thumbs up for a subcutaneous (SC) infliximab biosimilar candidate from Celltrion.
Panel: Insulin Biosimilar Competition May Be Scant at Best
Insulin is not a complex drug, but churning it out in massive quantities at high levels of purity is one of the main hurdles inhibiting biosimilar competition, panelists said.
Are Orphan Drug Biosimilars Too Costly and Difficult to Produce?
Potential developers of orphan drug biosimilars face daunting challenges to get these drugs approved and onto market, said a panel of experts.
Biosimilar Experts Debate Divergence in Regulatory Standards
Regulators want built-in flexibility, and that benefits biosimilar developers, but there can be a price for this amount of latitude, panelists said.
The Brexit Rollout From the Biosimilars Perspective
A renowned expert on the life sciences industry in the United Kingdom provides an insightful look at Brexit and the importance for the pharmaceutical sector.
AbbVie Accuses Alvotech of Trade Secret Piracy
The company claims in a suit that a former employee transferred high-concentration adalimumab trade secrets to his laptop and took those to a new job with Alvotech.